Platelet ADP receptor (P2RY1) polymorphism and the risk of inadequate platelet response to aspirin: Study in patients with ischemic stroke

Abstract

Abstract An estimated 5–60% of patients experience inadequate antiplatelet effects after taking aspirin. We investigated the gene variants that might determine the outcome of the aspirin response in stroke patients. A total of 293 ischemic stroke patients who were taking 150 mg of aspirin for more than 7 days, were enrolled and only 230 patients with serum salicylate levels > 30 µg/mL were included. Variants in COX1 (rs1236913 C > T), COX2 (rs20417 G > C), GpIIb/IIIa (rs5981 T > C), P2RY1 (rs701265 A > G & rs1371097 C > T), PEAR1 (rs2768759 C > A), ITGB3 (rs2317676 A > G) and UGT1A6 (rs1105879 A > G & rs2070959 A > C) were genotyped. Platelet aggregation tests were carried out by light transmittance aggregometry using adenosine-di-phosphate and arachidonic acid as agonists. The ‘T’ allele of P2RY1 (rs1371097 C > T) polymorphism was significantly associated with inadequate platelet response as measured by platelet aggregometry (OR, 95%, 1.71, 1.122–2.61; p = 0.0131). Presence of a single copy of the ‘T’ allele in P2RY1 (rs1371097 C > T) increased the risk of inadequate response by 3.46 times (adjusted OR (95%), 3.46 (0.043); p = 0.043).